Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

This study is testing a new type of MRI contrast agent called MT218 specifically designed to target prostate cancer. The goal is to see whether this targeted agent can provide better imaging of high-grade prostate tumors compared to standard MRI. **You may be eligible if...** - You are a man older than 18 - You have confirmed high-grade prostate cancer (Gleason score 8–10) - You have already had at least one standard prostate MRI and biopsy - Your kidney function is good (GFR above 60 mL/min within 30 days of the study MRI) - You are able to lie still for an MRI **You may NOT be eligible if...** - You have active kidney or liver disease - You have active prostatitis, severe benign prostate enlargement, or a urinary tract infection - You have uncontrolled diabetes or high blood pressure - You have another active cancer besides prostate cancer - You have metal implants or devices that prevent MRI (like a pacemaker or cochlear implant) - You have had major surgery or a prostate biopsy within the past 4 weeks - You are participating in another clinical trial Talk to your doctor to see if this trial is right for you.